Premium
A PHASE 1/1B DOSE‐ESCALATION TRIAL EVALUATING CPI‐818, AN ORAL INTERLEUKIN‐2‐INDUCIBLE T‐CELL KINASE INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY T‐CELL LYMPHOMA
Author(s) -
Mobasher M.,
Miller R.,
Janc J.,
Kwei L.,
Barker C.,
Mohammady A.,
Luciano G.,
Radeski D.,
Kim Y.,
Khodadoust M.,
Horwitz S.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.11_2632
Subject(s) - t cell , medicine , lymphoma , cancer research , t cell receptor , tumor microenvironment , cutaneous t cell lymphoma , t cell lymphoma , immunology , immune system , mycosis fungoides